首页> 外文期刊>European addiction research >International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder
【24h】

International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder

机译:关于筛查,诊断和治疗物质使用障碍患者的国际共识陈述,可紊乱缺陷/多动病症

获取原文
获取原文并翻译 | 示例
           

摘要

Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients with ADHD-SUD comorbidity.
机译:成人注意力缺陷/多动障碍(ADHD)经常与物质使用障碍(SUD)共同发生,并且与早期发作和抑制的早期发育和更严重的疗效相关联。 筛选工具允许良好地识别有可能的ADHD在苏打水中,应该经常使用,然后尽快启动ADHD诊断过程。 建议使用药物和心理治疗组合的ADHD和SUD的同时和综合治疗。 在对标准剂量无反应有助于标准剂量的患者中,可以考虑长效甲基酚,延长释放的副胺和氧氧杂物,并在患者对较高剂量中考虑。 本文包括制定的基于证据和基于共识的建议,以在筛查,诊断和治疗ADHD-SUD合并症患者的筛查,诊断和治疗方面提供指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号